Brief: Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
28/02/2024 13:36
Feb 28 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA COMPLETES SUCCESSFUL DOSE-RANGING STUDY OF
SPC-15
INTRANASAL THERAPEUTIC FOR PTSD
* SILO PHARMA INC- ON TRACK TO SUBMIT A PRE-INVESTIGATIONAL
NEW
DRUG APPLICATION TO FDA BY END OF Q2 2024
* SILO PHARMA INC: POSITIVE RESULTS FROM ITS NON-GLP SMALL
ANIMAL
DOSE-RANGING STUDY OF SPC-15
* SILO PHARMA INC: DATA ANALYSIS DEMONSTRATED RAPID
ABSORPTION OF
SPC-15 WITH GOOD EXPOSURE OVER A 24-HOUR PERIOD
Source text for Eikon: ID:nGNX94WB6Z
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement